Saturday, October 31, 2026

The Legend of Zelda: Tears of the Kingdom dominates video game sales

The Legend of Zelda: Tears of the Kingdom dominates video game sales

“The Legend of Zelda: Tears of the Kingdom” has finally arrived and is already bulldozing the sales of “Hogwarts Legacy.”

Announced back in 2019, “Tears of the Kingdom” is the direct sequel to 2017’s Nintendo Switch’s launch game “Breath of the Wild,” widely considered to be the best game in the nearly 40-year-old “Legend of Zelda” series and even considered by some as the finest video game ever made.

“Breath of the Wild” has sold nearly 30 million copies as of March 2023, making it the 4th best-selling game on Nintendo’s hybrid game system, the Switch, the 3rd best-selling game console ever with 126 million units sold.

However, the hype behind “Tears” might push both products further up in their respective lists since it is the kind of game that moves systems, especially with a Limited Edition allusive to the game made available at the same time, as it might also drum up interest in the older title.

While the “Tears” score on Metacritic is one point away from its predecessor, some critics consider it even better and a strong contender for the best game ever made.

Barely a week after its release, “Tears” had the second biggest Nintendo launch in the UK and has already doubled boxed sales of “Hogwarts Legacy” in the same territory, the latter being 2023’s best-selling title thus far having already totaled 15 million units sold and a $1 billion revenue for its publisher, Warner Bros, since its release in February.

It’s worth mentioning, though, that those figures, as impressive as they are, relate only to PC, PS5, and Xbox Series X/S, with ports for the PS4 and Xbox One released recently and a Switch release due in November. For the moment, however, “Tears” is beating “Hogwarts” soundly, which is impressive.

“The Legend of Zelda” series has always been one of Nintendo’s flagship franchises, with its consistent quality and sales numbers. Still, it always found itself somewhat eclipsed by its sibling IPs, “Super Mario” and “Pokémon,” the best-selling video game franchise and the highest-grossing media franchise, respectively.

Before “Breath of the Wild,” the best-selling “Zelda” was 2006’s “Twilight Princess” for the Gamecube and Wii, with just 8.6 million units sold… A far cry from the former’s total sales, showing that “Zelda” has become not just as gigantic as the Nintendo mentioned above’s franchises but rivaling other massive competing IPs such as Call of Duty, Minecraft, and Final Fantasy in popularity… The latter of which also has a new title launching this year.

Such is the overwhelming success of both “Tears” and the recently released “The Super Mario Bros Movie” that Nintendo is considering the possibility of “Zelda” transitioning to the silver screen.

Categories

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com